Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2022-07-11 M&A Activity
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
425 Filing
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content describes the entry into a material definitive agreement, specifically an Agreement and Plan of Merger between La Jolla Pharmaceutical Company and Innoviva, Inc. It details the terms of the merger, the tender offer, board approval, and related agreements. There is no financial statement or detailed financial performance data included, but rather a disclosure of a significant corporate transaction. This fits the category of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids. The document is not an Annual Report, Earnings Release, or other financial report type, nor is it a simple announcement of a report publication. Therefore, the appropriate classification is M&A Activity (TAR). The confidence is high given the clear description of merger agreement and related terms.
2022-07-11 English
SC 13E3/A
Regulatory Filings Classification · 95% confidence The document is a Schedule 13E-3 Amendment No. 2 filed with the SEC, which is a transaction statement related to a tender offer and merger under Rule 13e-3 of the Securities Exchange Act of 1934. It details the expiration and results of the tender offer, the acceptance for payment of shares, and the subsequent merger and delisting plans. The document is a regulatory filing specifically related to a merger transaction but is not itself a merger proxy statement or tender offer document like Schedule TO or Schedule 14D-9. It is a formal SEC filing reporting the transaction status and results. Given the nature of the filing and the specific form type (Schedule 13E-3 Amendment), the most appropriate classification is Regulatory Filings (RNS), as it does not fit the more specific M&A Activity (TAR) or Merger & Acquisition (MA) categories which are reserved for merger communications or proxy statements. The document is detailed and substantive but is a regulatory transaction statement rather than a full report or presentation.
2022-07-08 English
SC TO-T/A Filing
Merger & Acquisition Classification · 95% confidence The document is a Schedule TO/A filing, which is an amendment to a Tender Offer Statement under the Securities Exchange Act of 1934. It details the results of a tender offer, including the number of shares tendered, acceptance for payment, and the consummation of a merger. It also mentions the delisting of shares following the merger. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to a tender offer and merger transaction. This fits the category of Merger & Acquisition filings (MA), which include tender-offer forms and merger communications such as Schedule TO filings. The document is 7,416 characters long, contains substantive information about the tender offer and merger, and is not merely an announcement or certification. Therefore, the correct classification is MA with high confidence.
2022-07-08 English
SCHEDULE 13E-3/A
Merger & Acquisition Classification · 100% confidence The document is a Schedule 13E-3/A filing, which is a transaction statement filed under Rule 13e-3 of the Securities Exchange Act of 1934. It relates to a tender offer and merger transaction involving Innoviva, Inc. and Entasis Therapeutics Holdings Inc. The document includes detailed information about the transaction, references to related filings (Schedule TO, Schedule 14D-9), and amendments to the original Schedule 13E-3. This type of filing is specifically related to merger and acquisition activity and tender offers. It is not an annual report, earnings release, or other financial report, but a regulatory filing concerning a merger transaction. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (6633 characters) and content confirm it is a substantive filing, not just an announcement or certification.
2022-06-17 English
M&A Activity 2022
M&A Activity Classification · 100% confidence The document is a letter from Innoviva, Inc. to the SEC's Office of Mergers and Acquisitions, responding to comments from the SEC staff regarding previously filed Schedule 13E-3 and Schedule TO forms related to a merger transaction involving Entasis Therapeutics Holdings Inc. The letter discusses amendments to these filings, addresses SEC staff comments on disclosure details, fairness of the offer, and other regulatory compliance matters. The presence of Schedule 13E-3 and Schedule TO filings, which are specific to tender offers and going-private transactions, and the detailed discussion of amendments and responses to SEC comments, clearly indicate this document is related to merger and acquisition activity. It is not a full report like an annual or quarterly report, nor is it a proxy or voting result announcement. It is also not a certification or a general regulatory filing but a direct communication about M&A filings and amendments. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length (7997 characters) and content confirm it is not a brief announcement but a substantive response letter related to M&A filings.
2022-06-17 English
SC TO-T/A Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO/A filing, which is an amendment to a Tender Offer Statement under the Securities Exchange Act of 1934. It relates to a tender offer and going-private transaction involving Entasis Therapeutics Holdings Inc. and Innoviva, Inc. The content includes detailed information about the offer, fairness considerations, ownership percentages before and after the merger, conditions to the offer, and legal proceedings related to the tender offer. This type of filing is specifically related to merger and acquisition activity, particularly tender offers and going-private transactions. It is not an annual report, earnings release, or other financial report, but rather a regulatory filing concerning a takeover bid. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' with code TAR. Therefore, the correct classification is TAR with high confidence.
2022-06-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.